SEC Form 4 · accession 0001140361-26-036246
Roivant Sciences Ltd. · ROIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meghan Fitzgerald
Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001635088
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Sep 8, 2026 | M | 20,000 | $8.80 | A | 62,963 | D | |
| Common SharesF1 | Sep 8, 2026 | S | 20,000 | $39.90 | D | 42,963 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.80 | Sep 8, 2026 | M | 20,000 | D | — | Apr 19, 2033 | Common Stock | 20,000 | 18,578 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
- F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Remarks
Exhibit 24 - Power of Attorney